Generated by AI
iBio, Inc. is a biotechnology company focused on developing precision antibodies and other next-generation biologics for obesity, cardiometabolic disease, cancer, and other hard-to-treat conditions. The company uses artificial intelligence, advanced computational biology, and proprietary discovery platforms to identify and optimize antibody candidates against challenging therapeutic targets. Its current technology stack includes platforms designed for antibody engineering, masking, optimization, and epitope steering, which support preclinical research and early-stage pipeline development. iBio’s work is centered on improving the speed and precision of drug discovery for complex diseases, with an emphasis on antibody-based therapies and related biopharmaceutical programs. Founded in 2008 and headquartered in San Diego, California, iBio plays a niche role in the biotechnology market as a research-driven company advancing AI-enabled biologic discovery.
Website11750 Sorrento Valley Road
San Diego, CA, 92121
United States
The latest articles about IBIO.
Detailed price information for Ibio Inc (IBIO-Q) from The Globe and Mail including charting and trades.
Summary of Oct 21's posts. Generated by AI.
Summary of Jan 12's posts. Generated by AI.
2026-10-07. The following slide deck was published by iBio, Inc.
Summary of Oct 23's posts. Generated by AI.
Summary of Jan 9's posts. Generated by AI.
Investors talking about IBIO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.